[Forbes.com] Bitter Pill To Swallow: Can The US Market Bear The Cost Of Sovaldi?

Sovaldi, the new drug to treat and cure Hepatitis C has certainly caused quite an uproar in the US since its FDA approval in December of 2013.  At $1,000 per pill, the manufacturer, Gilead, has plenty of people and payers to answer to in order to justify this enormous cost, say industry experts and watchdogs.

With roughly 3 million patients in the US suffering from hepatitis C, the only options in the past were Interferon and Ribavirin which led to many side effects along with unpredictable responses. Moreover, the option of liver transplant and ongoing end of life care were previously the only options for this devastating disease.

Read More


Sign-up for updates

  • This field is for validation purposes and should be left unchanged.